NCT00920803 - A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2008

Primary Completion Date

November 11, 2009

Study Completion Date

November 11, 2009

Conditions

Neoplasms, Colorectal

Interventions

DRUG

Placebo

Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.

DRUG

SRT501

SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.

Trial Locations (1)

LE1 5WW

GSK Investigational Site, Leicester